NICE recommends ranibizumab for NHS

Article

Ranibizumab has been recommended for use within the NHS in England and Wales to treat macular oedema (ME) secondary to retinal vein occlusion (RVO).

Ranibizumab has been recommended for use within the NHS in England and Wales to treat macular oedema (ME) secondary to retinal vein occlusion (RVO).

The National Institute for Health and Clinical Excellence (NICE) issued a positive Final Appraisal Determination (FAD) outcome for ranibizumab as a treatment option for patients suffering from ME due to CRVO or BRVO where laser treatment would not be beneficial or appropriate. This is the third recommendation for ranibizumab, following approvals from the Scottish Medicines Consotrium (SMC) for the treatment of diabetic macular oedema (DME).

Intravitreal ranibizumab is the only anti-VEGF therapy currently licensed to treat RVOs and previous clinical trials have indicated it can achieve significant and sustained improvements in visual acuity.

Dr Ian Pearce, Consultant Ophthalmologist and Vitreoretinal Surgeon, St Paul’s Eye Unit, Royal Liverpool Hospital, stated, “The decision by NICE to recommend ranibizumab for the treatment of CRVO and BRVO is great news for people with these conditions.”

“The impact of the visual impairment we so often see in people with RVO can have a significant impact on a person’s quality of life," Dr Pearce continued. "Ranibizumab has been used to great success in the treatment of wet AMD for a number of years. It is an established and well-tolerated treatment which when used to treat RVO can lead to rapid and significant gains in vision. The impact of this cannot be underestimated as it can make the difference in a person’s ability to carry out everyday tasks such as reading and driving. I hope that following publication of final NICE Guidance we see its rapid implementation across the NHS.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.